# Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

> **NCT04279314** · PHASE3 · COMPLETED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 154 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **DRUG:** Trofinetide

## Key facts

- **NCT ID:** NCT04279314
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-29
- **Primary completion:** 2022-08-19
- **Final completion:** 2022-08-19
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04279314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04279314, "Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04279314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*